TFRC and hepatocellular carcinoma: Consistent with expectation, HepG2 cells treated with TF-Fe3+ NVs had higher levels of Fe2+ accumulation than the free NVs or TF NVs, confirming that TFRC could mediate the targeted delivery of Fe3+-binding NVs to HCC cells (Fig. 3D).